This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer
A landmark RCT of 40 overweight/obese participants found that pasteurized Akkermansia muciniphila supplementation for 3 months improved insulin sensitivity by 28% and reduced plasma LPS levels, a marker of gut barrier dysfunction, compared to placebo.
| Study | Participants | Finding | Quality |
|---|---|---|---|
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. — Nature Medicine (2019) | 40 | Pasteurized A. muciniphila improved insulin sensitivity, reduced insulinemia, and lowered plasma total cholesterol | High |
For overweight adults with metabolic concerns, pasteurized Akkermansia muciniphila at 10 billion cells/day for at least 3 months may improve insulin sensitivity and gut barrier integrity. The pasteurized form appears more effective and stable than live bacteria.
A randomized controlled trial examining the effects of pasteurized Akkermansia muciniphila supplementation on metabolic parameters, insulin sensitivity, and gut barrier integrity in overweight and obese adults.
Akkermansia muciniphila strengthens the gut barrier by promoting mucin production in the intestinal lining. Clinical trials show it reduces plasma LPS (endotoxin) levels, a key marker of "leaky gut." This improved barrier function is linked to better metabolic outcomes.
Yes. The landmark Nature Medicine trial found that pasteurized (heat-killed) Akkermansia muciniphila was actually more effective than live bacteria for improving insulin sensitivity and metabolic markers. The pasteurized form also has better shelf stability.
The primary clinical trial ran for 3 months and found significant metabolic improvements at that timepoint. Some gut barrier improvements may begin earlier, but plan for at least 3 months of consistent supplementation to see measurable metabolic changes.
Based on current evidence, overweight or obese adults with insulin resistance or metabolic syndrome markers may benefit most. The trial enrolled participants with BMI 25-35 and metabolic dysfunction. It is not yet tested for lean individuals or children.